ROYALTY PHARMA PLC- CL A (RPRX) Stock Fundamental Analysis
USA - NASDAQ:RPRX - GB00BMVP7Y09 - Common Stock
38.63 USD
-2.15 (-5.27%)
RPRX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. RPRX has an excellent profitability rating, but there are concerns on its financial health. RPRX may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
RPRX had positive earnings in the past year.
RPRX had a positive operating cash flow in the past year.
RPRX had positive earnings in each of the past 5 years.
In the past 5 years RPRX always reported a positive cash flow from operatings.
1.2 Ratios
RPRX's Return On Assets of 5.57% is amongst the best of the industry. RPRX outperforms 89.06% of its industry peers.
RPRX has a better Return On Equity (16.08%) than 90.10% of its industry peers.
With an excellent Return On Invested Capital value of 8.50%, RPRX belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for RPRX is significantly below the industry average of 15.44%.
The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(8.50%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.57% | ||
| ROE | 16.08% | ||
| ROIC | 8.5% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
Looking at the Profit Margin, with a value of 44.28%, RPRX belongs to the top of the industry, outperforming 98.44% of the companies in the same industry.
RPRX's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 79.84%, RPRX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of RPRX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 79.84% | ||
| PM (TTM) | 44.28% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so RPRX is still creating some value.
Compared to 1 year ago, RPRX has less shares outstanding
Compared to 5 years ago, RPRX has more shares outstanding
The debt/assets ratio for RPRX is higher compared to a year ago.
2.2 Solvency
RPRX has an Altman-Z score of 1.84. This is not the best score and indicates that RPRX is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of RPRX (1.84) is better than 63.54% of its industry peers.
The Debt to FCF ratio of RPRX is 11.22, which is on the high side as it means it would take RPRX, 11.22 years of fcf income to pay off all of its debts.
RPRX has a Debt to FCF ratio of 11.22. This is in the better half of the industry: RPRX outperforms 78.13% of its industry peers.
A Debt/Equity ratio of 1.10 is on the high side and indicates that RPRX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.10, RPRX is not doing good in the industry: 73.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.1 | ||
| Debt/FCF | 11.22 | ||
| Altman-Z | 1.84 |
ROIC/WACC1.05
WACC8.1%
2.3 Liquidity
RPRX has a Current Ratio of 1.26. This is a normal value and indicates that RPRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.26, RPRX is doing worse than 77.60% of the companies in the same industry.
A Quick Ratio of 1.26 indicates that RPRX should not have too much problems paying its short term obligations.
The Quick ratio of RPRX (1.26) is worse than 67.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.26 |
3. Growth
3.1 Past
RPRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.24%.
RPRX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -18.23% yearly.
The Revenue has decreased by -3.86% in the past year.
RPRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.52% yearly.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)-3.86%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
Based on estimates for the next years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.58% on average per year.
RPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.36% yearly.
EPS Next Y11.77%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
EPS Next 5Y12.58%
Revenue Next Year14.96%
Revenue Next 2Y8.31%
Revenue Next 3Y7.87%
Revenue Next 5Y10.36%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 9.40, which indicates a very decent valuation of RPRX.
90.10% of the companies in the same industry are more expensive than RPRX, based on the Price/Earnings ratio.
RPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.67.
The Price/Forward Earnings ratio is 7.63, which indicates a rather cheap valuation of RPRX.
Based on the Price/Forward Earnings ratio, RPRX is valued cheaply inside the industry as 89.58% of the companies are valued more expensively.
RPRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 31.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.4 | ||
| Fwd PE | 7.63 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, RPRX is valued a bit cheaper than the industry average as 79.17% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.59 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of RPRX may justify a higher PE ratio.
PEG (NY)0.8
PEG (5Y)N/A
EPS Next 2Y11.15%
EPS Next 3Y11.71%
5. Dividend
5.1 Amount
RPRX has a Yearly Dividend Yield of 2.16%.
Compared to an average industry Dividend Yield of 6.76, RPRX pays a better dividend. On top of this RPRX pays more dividend than 93.23% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, RPRX has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.16% |
5.2 History
RPRX has been paying a dividend for over 5 years, so it has already some track record.
RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
36.87% of the earnings are spent on dividend by RPRX. This is a low number and sustainable payout ratio.
DP36.87%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
NASDAQ:RPRX (11/7/2025, 3:03:07 PM)
38.63
-2.15 (-5.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.15%
Inst Owner Change0.3%
Ins Owners1.79%
Ins Owner Change52.31%
Market Cap22.53B
Revenue(TTM)2.26B
Net Income(TTM)1.02B
Analysts82.67
Price Target44.35 (14.81%)
Short Float %3.45%
Short Ratio3.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.16% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP36.87%
Div Incr Years4
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.44%
Min EPS beat(2)-59.9%
Max EPS beat(2)3.01%
EPS beat(4)3
Avg EPS beat(4)-10.84%
Min EPS beat(4)-59.9%
Max EPS beat(4)6.88%
EPS beat(8)5
Avg EPS beat(8)-4.24%
EPS beat(12)8
Avg EPS beat(12)-0.53%
EPS beat(16)9
Avg EPS beat(16)-6.35%
Revenue beat(2)2
Avg Revenue beat(2)6.9%
Min Revenue beat(2)4.2%
Max Revenue beat(2)9.61%
Revenue beat(4)2
Avg Revenue beat(4)-5.21%
Min Revenue beat(4)-20.42%
Max Revenue beat(4)9.61%
Revenue beat(8)2
Avg Revenue beat(8)-9.06%
Revenue beat(12)2
Avg Revenue beat(12)-11.79%
Revenue beat(16)4
Avg Revenue beat(16)-9.44%
PT rev (1m)0.48%
PT rev (3m)4.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.88%
EPS NY rev (1m)-0.33%
EPS NY rev (3m)4.74%
Revenue NQ rev (1m)0.7%
Revenue NQ rev (3m)-0.09%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)5.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.4 | ||
| Fwd PE | 7.63 | ||
| P/S | 9.77 | ||
| P/FCF | 31.59 | ||
| P/OCF | 9.36 | ||
| P/B | 3.55 | ||
| P/tB | 4.15 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY10.64%
EPS(NY)5.07
Fwd EY13.11%
FCF(TTM)1.22
FCFY3.17%
OCF(TTM)4.13
OCFY10.68%
SpS3.95
BVpS10.89
TBVpS9.3
PEG (NY)0.8
PEG (5Y)N/A
Graham Number31.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.57% | ||
| ROE | 16.08% | ||
| ROCE | 10.75% | ||
| ROIC | 8.5% | ||
| ROICexc | 9.3% | ||
| ROICexgc | 9.89% | ||
| OM | 79.84% | ||
| PM (TTM) | 44.28% | ||
| GM | N/A | ||
| FCFM | 30.93% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.1 | ||
| Debt/FCF | 11.22 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 73.45% | ||
| Interest Coverage | -8.39 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 69.86% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.26 | ||
| Altman-Z | 1.84 |
F-Score7
WACC8.1%
ROIC/WACC1.05
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y11.77%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
EPS Next 5Y12.58%
Revenue 1Y (TTM)-3.86%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year14.96%
Revenue Next 2Y8.31%
Revenue Next 3Y7.87%
Revenue Next 5Y10.36%
EBIT growth 1Y91.7%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year28.89%
EBIT Next 3Y14.6%
EBIT Next 5Y13.36%
FCF growth 1Y36.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.52%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 5 / 10 to RPRX.
What is the valuation status of ROYALTY PHARMA PLC- CL A (RPRX) stock?
ChartMill assigns a valuation rating of 7 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
Can you provide the profitability details for ROYALTY PHARMA PLC- CL A?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.4 and the Price/Book (PB) ratio is 3.55.
Is the dividend of ROYALTY PHARMA PLC- CL A sustainable?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 5 / 10 and the dividend payout ratio is 36.87%.